Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Effects of Docosahexaenoic Acid and Its Peroxidation Product on Amyloid-β Peptide-Stimulated Microglia.

Geng X, Yang B, Li R, Teng T, Ladu MJ, Sun GY, Greenlief CM, Lee JC.

Mol Neurobiol. 2019 Nov 1. doi: 10.1007/s12035-019-01805-4. [Epub ahead of print]

PMID:
31677009
2.

The role of APOE in transgenic mouse models of AD.

Balu D, Karstens AJ, Loukenas E, Maldonado Weng J, York JM, Valencia-Olvera AC, LaDu MJ.

Neurosci Lett. 2019 Aug 10;707:134285. doi: 10.1016/j.neulet.2019.134285. Epub 2019 May 28. Review.

PMID:
31150730
3.

APOE genotype and sex affect microglial interactions with plaques in Alzheimer's disease mice.

Stephen TL, Cacciottolo M, Balu D, Morgan TE, LaDu MJ, Finch CE, Pike CJ.

Acta Neuropathol Commun. 2019 May 21;7(1):82. doi: 10.1186/s40478-019-0729-z.

4.

A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model.

Campagna J, Spilman P, Jagodzinska B, Bai D, Hatami A, Zhu C, Bilousova T, Jun M, Elias CJ, Pham J, Cole G, LaDu MJ, Jung ME, Bredesen DE, John V.

Sci Rep. 2018 Dec 4;8(1):17574. doi: 10.1038/s41598-018-35687-8.

5.

Cytosolic Phospholipase A2 Facilitates Oligomeric Amyloid-β Peptide Association with Microglia via Regulation of Membrane-Cytoskeleton Connectivity.

Teng T, Dong L, Ridgley DM, Ghura S, Tobin MK, Sun GY, LaDu MJ, Lee JC.

Mol Neurobiol. 2019 May;56(5):3222-3234. doi: 10.1007/s12035-018-1304-5. Epub 2018 Aug 15.

PMID:
30112630
6.

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease.

Ma QL, Teng E, Zuo X, Jones M, Teter B, Zhao EY, Zhu C, Bilousova T, Gylys KH, Apostolova LG, LaDu MJ, Hossain MA, Frautschy SA, Cole GM.

Neurobiol Dis. 2018 Jun;114:120-128. doi: 10.1016/j.nbd.2018.02.014. Epub 2018 Mar 6.

PMID:
29501530
7.

Prion protein inhibits fast axonal transport through a mechanism involving casein kinase 2.

Zamponi E, Buratti F, Cataldi G, Caicedo HH, Song Y, Jungbauer LM, LaDu MJ, Bisbal M, Lorenzo A, Ma J, Helguera PR, Morfini GA, Brady ST, Pigino GF.

PLoS One. 2017 Dec 20;12(12):e0188340. doi: 10.1371/journal.pone.0188340. eCollection 2017.

8.

EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.

Tai LM, Balu D, Avila-Munoz E, Abdullah L, Thomas R, Collins N, Valencia-Olvera AC, LaDu MJ.

J Lipid Res. 2017 Sep;58(9):1733-1755. doi: 10.1194/jlr.R076315. Epub 2017 Apr 7. Review.

9.

APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease.

Abdullah L, Evans JE, Emmerich T, Crynen G, Shackleton B, Keegan AP, Luis C, Tai L, LaDu MJ, Mullan M, Crawford F, Bachmeier C.

Aging (Albany NY). 2017 Mar 23;9(3):964-985. doi: 10.18632/aging.101203.

10.
11.

Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE.

Koster KP, Smith C, Valencia-Olvera AC, Thatcher GR, Tai LM, LaDu MJ.

Curr Top Med Chem. 2017;17(6):708-720. Review.

PMID:
27320328
12.

Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain.

Teter B, LaDu MJ, Sullivan PM, Frautschy SA, Cole GM.

Neuroreport. 2016 Aug 3;27(11):791-5. doi: 10.1097/WNR.0000000000000608.

13.

Erratum to: A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.

Luo J, Lee SH, VandeVrede L, Qin Z, Aissa MB, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A, Koster K, Tai LM, LaDu MJ, Bennett BM, Thatcher GR.

Mol Neurodegener. 2016 May 18;11(1):40. No abstract available.

14.

A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease.

Luo J, Lee SH, VandeVrede L, Qin Z, Ben Aissa M, Larson J, Teich AF, Arancio O, D'Souza Y, Elharram A, Koster K, Tai LM, LaDu MJ, Bennett BM, Thatcher GR.

Mol Neurodegener. 2016 Apr 29;11:35. doi: 10.1186/s13024-016-0103-6. Erratum in: Mol Neurodegener. 2016;11(1):40.

15.

APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.

Zhou M, Huang T, Collins N, Zhang J, Shen H, Dai X, Xiao N, Wu X, Wei Z, York J, Lin L, Zhu Y, LaDu MJ, Chen X.

Curr Alzheimer Res. 2016;13(9):1048-55.

PMID:
27087442
16.

The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer's disease of humans and mice.

Cacciottolo M, Christensen A, Moser A, Liu J, Pike CJ, Smith C, LaDu MJ, Sullivan PM, Morgan TE, Dolzhenko E, Charidimou A, Wahlund LO, Wiberg MK, Shams S, Chiang GC; Alzheimer's Disease Neuroimaging Initiative, Finch CE.

Neurobiol Aging. 2016 Jan;37:47-57. doi: 10.1016/j.neurobiolaging.2015.10.010. Epub 2015 Oct 19.

17.

Genetics ignite focus on microglial inflammation in Alzheimer's disease.

Malik M, Parikh I, Vasquez JB, Smith C, Tai L, Bu G, LaDu MJ, Fardo DW, Rebeck GW, Estus S.

Mol Neurodegener. 2015 Oct 5;10:52. doi: 10.1186/s13024-015-0048-1. Review.

18.

APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective.

Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N, Green SJ, Hendrickson B, Van Eldik LJ, LaDu MJ.

J Neurochem. 2015 May;133(4):465-88. doi: 10.1111/jnc.13072. Epub 2015 Mar 18. Review.

19.

Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.

Tai LM, Koster KP, Luo J, Lee SH, Wang YT, Collins NC, Ben Aissa M, Thatcher GR, LaDu MJ.

J Biol Chem. 2014 Oct 31;289(44):30538-55. doi: 10.1074/jbc.M114.600833. Epub 2014 Sep 12.

20.

Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition.

Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW.

J Neuroinflammation. 2014 Jun 19;11:111. doi: 10.1186/1742-2094-11-111.

21.

White matter integrity is associated with cerebrospinal fluid markers of Alzheimer's disease in normal adults.

Gold BT, Zhu Z, Brown CA, Andersen AH, LaDu MJ, Tai L, Jicha GA, Kryscio RJ, Estus S, Nelson PT, Scheff SW, Abner E, Schmitt FA, Van Eldik LJ, Smith CD.

Neurobiol Aging. 2014 Oct;35(10):2263-71. doi: 10.1016/j.neurobiolaging.2014.04.030. Epub 2014 May 2.

22.

Soluble apoE/Aβ complex: mechanism and therapeutic target for APOE4-induced AD risk.

Tai LM, Mehra S, Shete V, Estus S, Rebeck GW, Bu G, LaDu MJ.

Mol Neurodegener. 2014 Jan 4;9:2. doi: 10.1186/1750-1326-9-2. Review.

23.

APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.

Kunzler J, Youmans KL, Yu C, Ladu MJ, Tai LM.

Neurosci Lett. 2014 Feb 7;560:131-6. doi: 10.1016/j.neulet.2013.12.032. Epub 2013 Dec 22.

24.

ApoE4 delays dendritic spine formation during neuron development and accelerates loss of mature spines in vitro.

Nwabuisi-Heath E, Rebeck GW, Ladu MJ, Yu C.

ASN Neuro. 2014 Jan 13;6(1):e00134. doi: 10.1042/AN20130043.

25.

Apolipoprotein E as a β-amyloid-independent factor in Alzheimer's disease.

Wolf AB, Valla J, Bu G, Kim J, LaDu MJ, Reiman EM, Caselli RJ.

Alzheimers Res Ther. 2013 Sep 3;5(5):38. doi: 10.1186/alzrt204. eCollection 2013. Review.

26.

Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, Van Eldik LJ, Fardo DW, Estus S, Bu G, Gylys KH, Ladu MJ.

J Biol Chem. 2013 Feb 22;288(8):5914-26. doi: 10.1074/jbc.M112.442103. Epub 2013 Jan 4.

27.

Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms.

Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G.

J Biol Chem. 2012 Dec 28;287(53):44593-601. doi: 10.1074/jbc.M112.420224. Epub 2012 Nov 6.

28.

APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease.

Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, Ladu MJ.

J Biol Chem. 2012 Dec 7;287(50):41774-86. doi: 10.1074/jbc.M112.407957. Epub 2012 Oct 11.

29.

Simultaneous analysis of dendritic spine density, morphology and excitatory glutamate receptors during neuron maturation in vitro by quantitative immunocytochemistry.

Nwabuisi-Heath E, LaDu MJ, Yu C.

J Neurosci Methods. 2012 Jun 15;207(2):137-47. doi: 10.1016/j.jneumeth.2012.04.003. Epub 2012 Apr 10.

30.

Intraneuronal Aβ detection in 5xFAD mice by a new Aβ-specific antibody.

Youmans KL, Tai LM, Kanekiyo T, Stine WB Jr, Michon SC, Nwabuisi-Heath E, Manelli AM, Fu Y, Riordan S, Eimer WA, Binder L, Bu G, Yu C, Hartley DM, LaDu MJ.

Mol Neurodegener. 2012 Mar 16;7:8. doi: 10.1186/1750-1326-7-8.

31.

APOE genotype alters glial activation and loss of synaptic markers in mice.

Zhu Y, Nwabuisi-Heath E, Dumanis SB, Tai LM, Yu C, Rebeck GW, LaDu MJ.

Glia. 2012 Apr;60(4):559-69. doi: 10.1002/glia.22289. Epub 2012 Jan 6.

32.

Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

LaDu MJ, Munson GW, Jungbauer L, Getz GS, Reardon CA, Tai LM, Yu C.

Biochim Biophys Acta. 2012 Feb;1821(2):295-302. doi: 10.1016/j.bbalip.2011.11.005. Epub 2011 Nov 23.

33.

Introducing Human APOE into Aβ Transgenic Mouse Models.

Tai LM, Youmans KL, Jungbauer L, Yu C, Ladu MJ.

Int J Alzheimers Dis. 2011;2011:810981. doi: 10.4061/2011/810981. Epub 2011 Oct 19.

34.

Development and validation of a yeast high-throughput screen for inhibitors of Aβ₄₂ oligomerization.

Park SK, Pegan SD, Mesecar AD, Jungbauer LM, LaDu MJ, Liebman SW.

Dis Model Mech. 2011 Nov;4(6):822-31. doi: 10.1242/dmm.007963. Epub 2011 Aug 2.

35.

Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations.

Youmans KL, Leung S, Zhang J, Maus E, Baysac K, Bu G, Vassar R, Yu C, LaDu MJ.

J Neurosci Methods. 2011 Mar 15;196(1):51-9. doi: 10.1016/j.jneumeth.2010.12.025. Epub 2011 Jan 8.

36.

Preparing synthetic Aβ in different aggregation states.

Stine WB, Jungbauer L, Yu C, LaDu MJ.

Methods Mol Biol. 2011;670:13-32. doi: 10.1007/978-1-60761-744-0_2.

37.

Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.

Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L.

J Biol Chem. 2010 Nov 19;285(47):36958-68. doi: 10.1074/jbc.M110.127829. Epub 2010 Sep 16.

38.

Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal Abeta42 uptake and lysosomal trafficking.

Fuentealba RA, Liu Q, Zhang J, Kanekiyo T, Hu X, Lee JM, LaDu MJ, Bu G.

PLoS One. 2010 Jul 29;5(7):e11884. doi: 10.1371/journal.pone.0011884.

39.

Endocytic pathways mediating oligomeric Abeta42 neurotoxicity.

Yu C, Nwabuisi-Heath E, Laxton K, Ladu MJ.

Mol Neurodegener. 2010 May 17;5:19. doi: 10.1186/1750-1326-5-19.

40.

Proposed mechanism for lipoprotein remodelling in the brain.

Yu C, Youmans KL, LaDu MJ.

Biochim Biophys Acta. 2010 Aug;1801(8):819-23. doi: 10.1016/j.bbalip.2010.05.001. Epub 2010 May 12. Review.

41.

Cognitive effects of cell-derived and synthetically derived Aβ oligomers.

Reed MN, Hofmeister JJ, Jungbauer L, Welzel AT, Yu C, Sherman MA, Lesné S, LaDu MJ, Walsh DM, Ashe KH, Cleary JP.

Neurobiol Aging. 2011 Oct;32(10):1784-94. doi: 10.1016/j.neurobiolaging.2009.11.007. Epub 2010 Jan 19.

42.

ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo.

Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, Weeber EJ, Turner RS, Xu B, Rebeck GW, Hoe HS.

J Neurosci. 2009 Dec 2;29(48):15317-22. doi: 10.1523/JNEUROSCI.4026-09.2009.

43.

ApoE isoform-dependent changes in hippocampal synaptic function.

Korwek KM, Trotter JH, Ladu MJ, Sullivan PM, Weeber EJ.

Mol Neurodegener. 2009 May 27;4:21. doi: 10.1186/1750-1326-4-21.

44.

Preparation of fluorescently-labeled amyloid-beta peptide assemblies: the effect of fluorophore conjugation on structure and function.

Jungbauer LM, Yu C, Laxton KJ, LaDu MJ.

J Mol Recognit. 2009 Sep-Oct;22(5):403-13. doi: 10.1002/jmr.948.

45.

The generation and function of soluble apoE receptors in the CNS.

Rebeck GW, LaDu MJ, Estus S, Bu G, Weeber EJ.

Mol Neurodegener. 2006 Oct 24;1:15.

46.

Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation.

Manelli AM, Bulfinch LC, Sullivan PM, LaDu MJ.

Neurobiol Aging. 2007 Aug;28(8):1139-47. Epub 2006 Jul 11.

47.

Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus.

Yun SH, Gamkrelidze G, Stine WB, Sullivan PM, Pasternak JF, Ladu MJ, Trommer BL.

Neurosci Lett. 2006 Jul 31;403(1-2):162-5. Epub 2006 Jun 12.

48.
49.

Blockade of nicotinic acetylcholine receptors suppresses hippocampal long-term potentiation in wild-type but not ApoE4 targeted replacement mice.

Yun SH, Park KA, Sullivan P, Pasternak JF, Ladu MJ, Trommer BL.

J Neurosci Res. 2005 Dec 15;82(6):771-7.

PMID:
16273551
50.

Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation.

White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ.

Neurobiol Dis. 2005 Apr;18(3):459-65.

PMID:
15755672

Supplemental Content

Support Center